Nexag (Tranexamic Acid)

Tranexamic Acid, the active ingredient in Nexag, is an antifibrinolytic presented as an oral tablet for systemic use. It helps reduce excessive bleeding by stabilizing blood clots and is employed in the management of heavy menstrual bleeding, nosebleeds, and peri‑operative hemorrhage in adult patients. It is approved for use in the European Union and is available by prescription.

GNH USA supplies Nexag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Tranexamic Acid reduces bleeding by inhibiting fibrinolysis in several clinical settings. - Menorrhagia: decreases menstrual blood loss and improves quality of life. - Epistaxis: shortens duration and volume of nosebleeds. - Surgical bleeding: minimizes intra‑operative and post‑operative blood loss.

Tranexamic Acid is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild stomach upset occurring in some patients. - Vomiting: occasional emesis, usually transient. - Diarrhea: loose stools reported. - Abdominal pain: discomfort in the gastrointestinal tract. - Headache: mild to moderate intensity. - Dyspepsia: indigestion or heartburn.

Serious or Rare Side Effects: - Thromboembolic events: formation of clots in veins or arteries. - Hypotension: sudden drop in blood pressure, especially with rapid IV administration. - Allergic reactions: rash, itching, or anaphylaxis. - Visual disturbances: blurred vision or retinal changes. - Seizures: rare neurologic events, particularly at high doses.

When prescribing Tranexamic Acid, clinicians should consider several safety precautions to minimize risk. - Assess thrombotic risk: evaluate history of deep‑vein thrombosis or pulmonary embolism. - Monitor renal function: adjust use in patients with impaired kidney clearance. - Use with caution in cardiovascular disease: consider potential for clot propagation. - Avoid in active intravascular clotting: contraindicated when clot formation is ongoing. - Review concomitant anticoagulants: balance bleeding and clotting risks. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Tranexamic Acid may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Combined with other antifibrinolytics (e.g., aprotinin): may excessively increase clot stability. - Concurrent use with procoagulant agents (e.g., activated factor VII): heightened risk of thrombosis.

Moderate Interactions (Monitor Closely): - Hormonal contraceptives: may augment clotting potential, monitor for signs of thrombosis. - Anticoagulants (e.g., warfarin, DOACs): may reduce anticoagulant effect, check coagulation parameters. - Certain antibiotics (e.g., erythromycin): can alter plasma levels, observe for adverse reactions.